advanced cancer, delirium
Conditions
Interventions
On admission to the medical oncology ward all patients with advanced cancer will be asked to participate in this study. Consenting patients will be submitted to delirium observation screening accordin
17,75 diagnosis of delirium is confirmed. (see appendix Flow sheet study design)
When diagnosis for delirium is confirmed by DRS-R-98 (DRS-R-98 total score is ≥
17,75), treatment of all patients will consist of identification and management of underlying aetiologies of delirium if possible and adding neuroleptic medication for symptom control. Patients will b
Sponsors
VU University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient has been diagnosed with advanced cancer; 2. Age ≥ 18; 3. Patient or his / her significant other speaks Dutch fluently.
Exclusion criteria
Exclusion criteria: 1. Delirium is due to alcohol withdrawal; 2. Patient has been diagnosed with glaucoma, Parkinson’s disease or dementia; 3. Patient is being treated with other neuroleptic medication or lithium; 4. Patient has another psychiatric disorder that is considered (by investigator) to interfere with assessment of delirium; 5. Patient had a QTc-interval of > 480 msec on ECG made on admission; 6. Patient has a history of neuroleptic malignant syndrome; 7. Patient has a history of convulsions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint for this trial is a DRS-R-98 severity rating score < 15,2518, as this is a measure for establishing clearance of delirium. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint is the amount of time elapsed between start of treatment and diminishing of the signs of delirium (DOS < 3, DSR-R-98 < 15,25). | — |
Contacts
Public ContactH.M.W. Verheul
De Boelelaan 1117
Outcome results
None listed